-
公开(公告)号：US20190338017A1
公开(公告)日：2019-11-07
申请号：US16513859
申请日：2019-07-17
Applicant: Theraclone Sciences, Inc. , International AIDS Vaccine Initiative , The Scripps Research Institute
Inventor： Po-Ying Chan-Hui , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Marjorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos , Stephen Kaminsky
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
-
公开(公告)号：US20190169273A1
公开(公告)日：2019-06-06
申请号：US16275936
申请日：2019-02-14
Applicant: Theraclone Sciences, Inc. , International AIDS Vaccine Initiative , The Scripps Research Institute
Inventor： Po-Ying Chan-Hui , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Marjorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos , Stephen Kaminsky
IPC: C07K16/10
CPC classification number: C07K16/1045 , A61K39/21 , A61K2039/505 , A61P31/14 , C07K16/1063 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
-
公开(公告)号：US20190031742A1
公开(公告)日：2019-01-31
申请号：US15918343
申请日：2018-03-12
Applicant: Theraclone Sciences, Inc. , International AIDS Vaccine Initiative , The Scripps Research Institute
Inventor： Po-Ying Chan-Hui , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Marjorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos , Stephen Kaminsky
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
-
4.发明申请BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODY 审中-公开人类免疫缺陷病毒1型（HIV-1）GP120特异性单克隆抗体的中和公开(公告)号：US20160264649A1
公开(公告)日：2016-09-15
申请号：US15152630
申请日：2016-05-12
Applicant: Theraclone Sciences, Inc. , The Scripps Research Institute , International AIDS Vaccine Initiative
Inventor： Po-Ying Chan-Hui , Katherine Doores , Michael Huber , Stephen Kaminsky , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Majorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos
IPC: C07K16/10
CPC classification number: C07K16/1063 , A61K39/21 , A61K2039/505 , C07K16/1045 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
Abstract translation: 本发明提供了一种获得广泛中和抗体（bNab）的方法，包括筛选来自供体PBMC样品的记忆B细胞培养物，以抵抗多种HIV-1物种的中和活性，克隆显示广泛中和活性的记忆B细胞; 并从该记忆B细胞培养物中拯救单克隆抗体。 所得到的单克隆抗体的特征在于它们以天然或单体形式选择性地结合来自Env蛋白的表位的能力，以及抑制HIV-1物种从多个进化枝的感染的能力。 提供了含有用于预防，诊断和治疗HIV感染的人单克隆抗HIV抗体的组合物。 提供了通过使用来自gp120的可变环内的保守区域的表位进行免疫来产生这种抗体的方法。 还提供了产生抗艾滋病毒1型免疫球蛋白的免疫原。 此外，提供了使用合适表位的疫苗接种方法。
-
公开(公告)号：US20140328797A1
公开(公告)日：2014-11-06
申请号：US14263305
申请日：2014-04-28
Applicant: Theraclone Sciences, Inc.
Inventor： Po-Ying Chan-Hui, III , Kristine Swiderek
IPC: A61K39/42 , A61K39/125 , A61K45/06 , C07K16/10 , C12N7/00
CPC classification number: A61K39/125 , A61K39/00 , A61K45/06 , C07K16/1009 , C07K2317/21 , C07K2317/33 , C07K2317/76
Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
Abstract translation: 本发明提供了分离的完全人单克隆抗-HRV抗体，以及制备和使用这些抗体的方法。 本发明的抗-HRV抗体预防或治疗患有HRV感染的受试者和相关疾病，包括但不限于感冒，鼻咽炎，痉挛，肺炎，细支气管炎，哮喘，慢性阻塞性肺病（COPD），鼻窦炎 ，细菌超感染和囊性纤维化。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20200024330A1
公开(公告)日：2020-01-23
申请号：US16591175
申请日：2019-10-02
Applicant: THERACLONE SCIENCES, INC. , THE SCRIPPS RESEARCH INSTITUTE , INTERNATIONAL AIDS VACCINE INITIATIVE
Inventor： Po-Ying Chan-Hui , Katherine Doores , Michael Huber , Stephen Kaminsky , Steven Frey , Ole Olesen , Jennifer Mitchum , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Majorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided
-
公开(公告)号：US10407493B2
公开(公告)日：2019-09-10
申请号：US16275936
申请日：2019-02-14
Applicant: Theraclone Sciences, Inc. , International AIDS Vaccine Initiative , The Scripps Research Institute
Inventor： Po-Ying Chan-Hui , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Marjorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos , Stephen Kaminsky
IPC: A61K39/00 , C07K16/28 , A61K39/395 , C07K14/00 , G01N33/574 , C07K16/10
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
-
8.发明授权公开(公告)号：US10087239B2
公开(公告)日：2018-10-02
申请号：US15152630
申请日：2016-05-12
Applicant: Theraclone Sciences, Inc. , The Scripps Research Institute , International AIDS Vaccine Initiative
Inventor： Po-Ying Chan-Hui , Katherine Doores , Michael Huber , Stephen Kaminsky , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Majorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
-
9.发明申请公开(公告)号：US20180057570A1
公开(公告)日：2018-03-01
申请号：US15701679
申请日：2017-09-12
Applicant: Theraclone Sciences, Inc. , The Scripps Research Institute , International AIDS Vaccine Initiative
Inventor： Po-Ying Chan-Hui , Katherine Doores , Michael Huber , Stephen Kaminsky , Steven Frey , Ole Olsen , Jennifer Mitcham , Matthew Moyle , Sanjay K. Phogat , Dennis R. Burton , Laura Majorie Walker , Pascal Raymond Georges Poignard , Wayne Koff , Melissa Danielle De Jean De St. Marcel Simek-Lemos
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
-
公开(公告)号：US20150086555A1
公开(公告)日：2015-03-26
申请号：US14557515
申请日：2014-12-02
Applicant: Theraclone Sciences, Inc.
Inventor： Ole Olsen , Christina L. Boozer
CPC classification number: C07K16/1018 , A61K39/395 , A61K39/42 , A61K45/06 , A61K47/6803 , A61K47/6841 , A61K49/00 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , G01N33/56983 , G01N2333/11 , G01N2469/10 , A61K2300/00
Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.
Abstract translation: 本发明提供新型人类抗流感抗体及相关组合物和方法。 这些抗体用于预防，抑制，中和，诊断和治疗流感感染。
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.07 seconds)
